Novel Plasma and Imaging Biomarkers in Heart Failure with Preserved Ejection Fraction

Overview

Journal Int J Cardiol Heart Vasc

Date 2017 Aug 9

PMID 28785707

Citations 2

Authors

Prathap Kanagala

Iain B Squire

Leong L Ng

Gerry P McCann

Affiliations

Soon will be listed here.

Abstract

Existing diagnostic guidelines for heart failure with preserved ejection fraction () primarily comprise natriuretic peptides and echocardiographic assessment, highlighting the role of diastolic dysfunction. However, recent discoveries of novel plasma markers implicated in pathophysiology of heart failure and technological advances in imaging provide additional biomarkers which are potentially applicable to . The evidence base for plasma extra-cellular matrix (ECM) peptides, galectin-3, ST2, GDF-15 and pentraxin-3 is reviewed. Furthermore, the capabilities of novel imaging techniques to assess existing parameters (e.g. left ventricular ejection fraction, systolic & diastolic function, chamber size) and additional derangements of the ECM, myocardial mechanics and ischaemia evaluation are addressed.

Citing Articles

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

Bilak J, Alam U, Miller C, McCann G, Arnold J, Kanagala P Card Fail Rev. 2022; 8:e24.

PMID: 35846985 PMC: 9274364. DOI: 10.15420/cfr.2022.12.

Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.

Kanagala P, Arnold J, Singh A, Chan D, Cheng A, Khan J PLoS One. 2020; 15(4):e0232280.

PMID: 32349122 PMC: 7190371. DOI: 10.1371/journal.pone.0232280.

References

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Shah R, Chen-Tournoux A, Picard M, Van Kimmenade R, Januzzi J . Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8):826-32. PMC: 2913048. DOI: 10.1093/eurjhf/hfq091. View

de Boer R, Lok D, Jaarsma T, van der Meer P, Voors A, Hillege H . Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2010; 43(1):60-8. PMC: 3028573. DOI: 10.3109/07853890.2010.538080. View

Bastarrika G, Zudaire B, Ferreira M, Arraiza M, Saiz-Mendiguren R, Rabago G . Assessment of left atrial volumes and function in orthotopic heart transplant recipients by dual-source CT: comparison with MRI. Invest Radiol. 2009; 45(2):72-6. DOI: 10.1097/RLI.0b013e3181c4f535. View

White S, Sado D, Flett A, Moon J . Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart. 2012; 98(10):773-9. DOI: 10.1136/heartjnl-2011-301515. View

Ahmed S, Clark L, Pennington W, Webb C, Bonnema D, Leonardi A . Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006; 113(17):2089-96. DOI: 10.1161/CIRCULATIONAHA.105.573865. View

Komajda M, Lam C . Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014; 35(16):1022-32. DOI: 10.1093/eurheartj/ehu067. View

Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F . Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006; 47(5):1043-8. DOI: 10.1016/j.jacc.2005.10.050. View

Tan Y, Wenzelburger F, Lee E, Nightingale P, Heatlie G, Leyva F . Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart. 2010; 96(13):1017-23. DOI: 10.1136/hrt.2009.189118. View

10.

Kato T, Noda A, Izawa H, Nishizawa T, Somura F, Yamada A . Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003; 42(2):278-85. DOI: 10.1016/s0735-1097(03)00573-4. View

11.

Hare J, Brown J, Marwick T . Performance of conventional echocardiographic parameters and myocardial measurements in the sequential evaluation of left ventricular function. Am J Cardiol. 2008; 101(5):706-11. DOI: 10.1016/j.amjcard.2007.10.037. View

12.

Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B . Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52(25):2166-74. PMC: 2637465. DOI: 10.1016/j.jacc.2008.09.027. View

13.

Santhanakrishnan R, Chong J, Ng T, Ling L, Sim D, Leong K . Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2012; 14(12):1338-47. DOI: 10.1093/eurjhf/hfs130. View

14.

Paulus W, van Ballegoij J . Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol. 2010; 55(6):526-37. DOI: 10.1016/j.jacc.2009.06.067. View

15.

Beanlands R, Chow B, Dick A, Friedrich M, Gulenchyn K, Kiess M . CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic.... Can J Cardiol. 2007; 23(2):107-19. PMC: 2650646. DOI: 10.1016/s0828-282x(07)70730-4. View

16.

McCullough P, Olobatoke A, Vanhecke T . Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2012; 12(4):200-10. DOI: 10.3909/ricm0624. View

17.

Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T . Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2007; 155(1):75-81. DOI: 10.1016/j.ahj.2007.08.013. View

18.

Park T, Nagueh S, Khoury D, Kopelen H, Akrivakis S, Nasser K . Impact of myocardial structure and function postinfarction on diastolic strain measurements: implications for assessment of myocardial viability. Am J Physiol Heart Circ Physiol. 2005; 290(2):H724-31. DOI: 10.1152/ajpheart.00714.2005. View

19.

Losi M, Memoli B, Contaldi C, Barbati G, Prete M, Betocchi S . Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodialysis. Nephrol Dial Transplant. 2010; 25(6):1950-4. DOI: 10.1093/ndt/gfp747. View

20.

Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K . Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011; 57(7):861-9. DOI: 10.1016/j.jacc.2010.10.018. View